User login
Key clinical point: Rates of ipsilateral breast tumor recurrence (IBTR) in patients with early breast cancer treated with lumpectomy and intraoperative radiation therapy (IORT) are higher than that reported in TARGIT-A trial and with traditional whole-breast radiation therapy or other forms of partial breast irradiation.
Major finding: At 5 years, the absolute IBTR rate was 6.6% for the entire IORT-treated cohort. IBTR rate was 8% and 1.2% for patients who received primary IORT and unintentional IORT boost treatment, respectively. No recurrences were observed in the delayed IORT or intentional-boost IORT cohorts.
Study details: Findings from an updated analysis of TARGIT-R with a 5-year follow-up assessment in 667 patients with early-stage breast cancer who underwent lumpectomy and IORT.
Disclosures: The study did not receive any funding. The lead author did not report any conflicts of interest, but some co-investigators reported relationships with various pharmaceutical companies.
Source: Valente SA et al. Ann Surg Oncol. 2021 Jan 12. doi: 10.1245/s10434-020-09432-3.
Key clinical point: Rates of ipsilateral breast tumor recurrence (IBTR) in patients with early breast cancer treated with lumpectomy and intraoperative radiation therapy (IORT) are higher than that reported in TARGIT-A trial and with traditional whole-breast radiation therapy or other forms of partial breast irradiation.
Major finding: At 5 years, the absolute IBTR rate was 6.6% for the entire IORT-treated cohort. IBTR rate was 8% and 1.2% for patients who received primary IORT and unintentional IORT boost treatment, respectively. No recurrences were observed in the delayed IORT or intentional-boost IORT cohorts.
Study details: Findings from an updated analysis of TARGIT-R with a 5-year follow-up assessment in 667 patients with early-stage breast cancer who underwent lumpectomy and IORT.
Disclosures: The study did not receive any funding. The lead author did not report any conflicts of interest, but some co-investigators reported relationships with various pharmaceutical companies.
Source: Valente SA et al. Ann Surg Oncol. 2021 Jan 12. doi: 10.1245/s10434-020-09432-3.
Key clinical point: Rates of ipsilateral breast tumor recurrence (IBTR) in patients with early breast cancer treated with lumpectomy and intraoperative radiation therapy (IORT) are higher than that reported in TARGIT-A trial and with traditional whole-breast radiation therapy or other forms of partial breast irradiation.
Major finding: At 5 years, the absolute IBTR rate was 6.6% for the entire IORT-treated cohort. IBTR rate was 8% and 1.2% for patients who received primary IORT and unintentional IORT boost treatment, respectively. No recurrences were observed in the delayed IORT or intentional-boost IORT cohorts.
Study details: Findings from an updated analysis of TARGIT-R with a 5-year follow-up assessment in 667 patients with early-stage breast cancer who underwent lumpectomy and IORT.
Disclosures: The study did not receive any funding. The lead author did not report any conflicts of interest, but some co-investigators reported relationships with various pharmaceutical companies.
Source: Valente SA et al. Ann Surg Oncol. 2021 Jan 12. doi: 10.1245/s10434-020-09432-3.